|
91
|
Statistics |
確認性臨床試驗資料缺失之指導原則
|
2019-11-26 |
|
92
|
Quality |
抗體藥物複合體藥品於品質研發策略指導原則
|
2019-11-26 |
|
93
|
Pharm/tox |
抗體藥物複合體藥品非臨床藥毒理研發策略指導原則
|
2019-11-26 |
|
94
|
Pharm/tox |
核醫放射性藥品非臨床藥毒理研發策略指導原則
|
2019-11-26 |
|
95
|
Product specific BE guideline |
Agomelatine Tablet_生體相等性試驗指導原則
|
2019-10-01 |
|
96
|
Product specific BE guideline |
Entecavir Tablet_生體相等性試驗指導原則
|
2019-10-01 |
|
97
|
Product specific BE guideline |
Levofloxacin Tablet_生體相等性試驗指導原則
|
2019-10-01 |
|
98
|
Product specific BE guideline |
Methylphenidate ER Tablet_生體相等性試驗指導原則
|
2019-10-01 |
|
99
|
Product specific BE guideline |
Oseltamivir Phosphate capsule_生體相等性試驗指導原則
|
2019-10-01 |
|
100
|
Product specific BE guideline |
Pazopanib tablet_生體相等性試驗指導原則
|
2019-10-01 |
